2011-2012年中国第三方医学检验行业研究报告 >> 水清木华研究中心

　　受市场发展较晚和医疗制度等影响，中国第三方医学检验行业尚处于发展初期，整体市场规模较小。目前中国从事第三方医学诊断市场规模不足20亿元，仅占医学诊断总收入的1%-2%。并且中国第三医学诊断市场可检验的项目仅1000多项，而国外发达国家如美国可达4000多项，医学诊断水平差距明显特别是基因/分子诊断细分市场。

　　目前中国从事第三方医学诊断的实验室约有110家，但大部分规模较小。金域、迪安、杭州艾迪康和高新达安（达安基因投资）是中国第三方医学诊断行业的龙头企业，市场份额合计占比70%左右，并且这四家企业均为连锁化经营的综合型诊断服务模式。而北京永瀚星港、北京迪诺、杭州致远等企业虽然市场份额占比较少，但凭借特色专项诊断服务也占据着一定的市场地位。

　　受下游市场需求刺激和鼓励民营医疗机构发展等诸多利好政策出台吸引，外资对中国第三方医学诊断市场的兴趣越来越大。目前已有众多外企通过技术合作或直接注资等形式进入中国第三医学诊断市场。

　　2012年初，达安基因(002030)与Life Technologies合资成立广州立菲达安诊断产品技术有限公司，并宣布正式启动基因测序分子诊断项目。

　　2012年2月，深圳华测检牵手Amcare国际医学实验室，在上海成立合资公司即Johns Hopkins(China) Medical Laboratories（合资公司注册资金1000万美金，双方股权比例为51%和49%），开展第三方医学检测服务。

　　2012年3月，康圣环球（北京）获2000万美元C轮投资，投资方为KPCB China、美国中经合集团(WI Harper Group)、Baird Capital Partners Asia和美国梅奥医学中心(Mayo Clinic)，其中，后三家企业也参与了2011年6月对康圣环球（北京）的B轮1100万美元投资。

《2011-2012年中国第三方医学诊断行业研究报告》主要包括以下几方面内容：

中国第三方医学诊断行业的准入政策、行业政策以及国际市场环境等；
中国第三方医学诊断行业的发展现状、竞争格局、发展前景及动态等；
上游诊断试剂、仪器和下游医疗机构等市场发展对中国第三方医学诊断行业的影响；
金域、迪安、杭州艾迪康、达安基因以及康圣环球（北京）等9家第三方医学诊断企业的经营现状、竞争优势以及发展前景等。

The independent clinical laboratory industry starts late and is still in its infancy in China, featuring a limited market size of less than RMB2 billion at present which just accounts for 1%-2% of the total revenue of medical diagnosis. Additionally, the independent clinical laboratories in home market can conduct 1,000 or more diagnostic items, while those in a developed country such as the U.S. are capable of carrying out as many as 4,000 diagnostic items. What is worse, China lags far behind developed countries in diagnostic levels, especially in genetic/molecular diagnostics market segment.

Currently, there are roughly 110 independent clinical laboratories in China, but most of them are small sized. Kingmed Diagnostics, Zhejiang D.A. Diagnostics, ADICON Clinical Laboratories, Inc. and Gaoxin-Da An (invested by DAAN Gene) are the leading companies in Chinese independent clinical laboratory industry and adopt comprehensive diagnostic service mode on the basis of chain operation, together making up approximately 70% market share. Although with a small portion of market share, Beijing NYMPHAVN Biotechnology, Beijing Adinovo Genetic Technology and Zhiyuan Medical Inspection Institute occupy a certain position in the market by virtue of special featured diagnostic service.

The demand from downstream market and the introduction of favorable policies like encouraging the development of private medical institutions arouse keen interest of foreign companies in Chinese independent clinical laboratory market. A large number of foreign enterprises have tapped into Chinese market through technical cooperation or direct capital injection.

In early 2012, DAAN Gene (002030) and Life Technologies co-founded Life Technologies DaAn Diagnostics and announced the official launch of DNA sequencing molecular diagnostics project.

In February 2012, Centre Testing International Corporation cooperated with Amcare Labs International in establishing Johns Hopkins (China) Medical Laboratories in Shanghai (registered capital of USD10 million and equity ratio of 51:49) to carry out the independent medical testing service.

In March 2012, Kindstar Global (Beijing) Medical Technology secured USD20 million in Series C funding from such investors as KPCB China, WI Harper Group, Baird Capital Partners Asia and Mayo Clinic, of which the latter three companies also participated in the company’s Series B financing of USD11 million in June 2011.

The report revolves around the followings:

The access policy, industrial policy, international market environment and so forth of Chinese independent clinical laboratory industry;
Status quo, competitive landscape, prospects and dynamics of Chinese independent clinical laboratory industry;
The effects of the development of upstream diagnostic reagent and instrument, and downstream medical institutions on Chinese independent clinical laboratory industry;
Operation, competitive advantages and prospects of 9 independent clinical laboratories including Kingmed Diagnostics, Zhejiang D.A. Diagnostics, ADICON Clinical Laboratories, Inc., DAAN Gene and Kindstar Global (Beijing) Medical Technology, etc.

第一章第三方医学诊断概述
1.1 定义
1.2 产业链

第二章中国第三方医学检验行业概况
2.1 政策环境
2.1.1 准入政策
2.1.2 行业政策
2.2 国际市场影响
2.2.1 市场现状
2.2.2 标杆企业分析
2.3 发展现状
2.4 竞争格局
2.5 发展前景及动态

第三章中国第三方医学检验上下游分析
3.1 上游市场对其影响
3.1.1 市场现状
3.1.2 产品结构
3.2 下游发展对其影响
3.2.1 第三方医学诊断市场容量巨大
3.2.2 医疗改革助推第三方医学诊断市场快速发展
3.2.3 需求多样化将促进第三方医学检验行业升级

第四章中国第三方医学检验主要企业
4.1 广州金域
4.1.1公司简介
4.1.2 经营现状及前景
4.2迪安诊断
4.2.1 公司简介
4.2.2 经营状况
4.2.3 营业构成分析
4.2.4 毛利率
4.2.5 客户及供应商
4.2.6 研发及投资分析
4.2.7 独立医学诊断服务
4.3达安基因
4.3.1 公司简介
4.3.2 经营状况
4.3.3 营收构成
4.3.5 毛利率
4.3.6 独立医学诊断业务
4.4北京永瀚星港
4.4.1 公司简介
4.4.2 经营状况
4.4.3 营收构成
4.4.4 毛利率
4.4.5 客户及供应商
4.4.6 研发及投资分析
4.5杭州艾迪康
4.6 北京德易
4.7北京迪诺
4.8杭州致远
4.9 康圣环球（北京）

1 Profile of Independent Clinical Laboratory
1.1 Definition
1.2 Industry Chain

2 Overview of China Independent Clinical Laboratory Industry
2.1 Policies
2.1.1 Access Policies
2.1.2 Industry Policies
2.2 Global Market
2.2.1 Status Quo
2.2.2 Model Enterprises
2.3 Current Development
2.4 Competitive Landscape
2.5 Dynamics and Prospects

3 Upstream and Downstream Industry of China Independent Clinical Laboratory
3.1 Upstream Sector
3.1.1 Status Quo
3.1.2 Product Mix
3.2 Downstream Sector
3.2.1 Huge Market Scale of Chinese Independent Clinical Laboratory
3.2.2 Medical Reform Encourages Rapid Development of Independent Clinical Laboratory in China
3.2.3 Diversified Demand Promotes the Upgrading of Independent Clinical Laboratory Industry in China

4 Key Players in China
4.1 Kingmed Diagnostics Co., Ltd
4.1.1 Profile
4.1.2 Operation and Prospects
4.2 Zhejiang D.A. Diagnostics Co., Ltd
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Clients and Suppliers
4.2.6 R & D and Investment
4.2.7 Independent Clinical Laboratory Service
4.3 DAAN Gene Co., Ltd
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.5 Gross Margin
4.3.6 Independent Clinical Laboratory Service
4.4 Beijing NYMPHAVN Biotechnology Corporation Ltd
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Clients and Suppliers
4.4.6 R & D and Investment
4.5 ADICON Clinical Laboratories, Inc
4.6 Beijing Deyi Biotechnology Medical Co., Ltd
4.7 Beijing Adinovo Genetic Technology Co., Ltd
4.8 Zhiyuan Medical Inspection Institute Co., Ltd
4.9 Kindstar Global (Beijing) Medical Technology Co., Ltd

图：独立医学诊断产业链示意图
图：中美独立医学诊断需求承接方对比
表：2010-2011年中国第三方医学诊断行业相关政策
图：2003-2010年美国独立医学检验行业的各检验项目市场占比
图：2010年美国医学检验市场份额（按需求承接方）
图：2007-2011年Quest Diagnostics营业收入与利润
图：2011年Quest Diagnostics(分业务)收入构成
表：2006-2011年Quest Diagnostics主要并购事件
图：2007-2011年Labcorp销售收入与利润
表：2009-2011年Labcorp（分业务）营业收入
表：2007-2011年Labcorp主要并购事件
表：美国麻省总医院和国内某三甲医院前五位外送检验项目对比
表：截止2011年底中国主要第三方医学检验企业基本特点及市场份额
图：2007-2014年中国体外诊断行业市场规模及增长率
图：2007-2014年中国体外诊断试剂市场规模及增长率
图：2011年中国体外诊断试剂构成
表：2010年中国各医疗机构的业务收入与检查收入
图：2008-2011年中国医院和基层医疗机构就诊人数
图：2008-2011年中国公立医院和民营医院数量
图：迪安诊断的独立诊断实验室布局
表：2008-2012年迪安诊断营业收入和利润
图：2008-2011年迪安诊断（分产品）营业收入
图：2008-2011年迪安诊断（分产品）营业收入构成
表：2008-2011年迪安诊断（分地区）营业收入
图：2008-2011年迪安诊断（分地区）营收构成
图：2008-2011年迪安诊断（分产品）毛利率
图：2008-2011年迪安诊断前五客户收入贡献及占同期营业收入的比重
表：2009-2011年迪安诊断前五客户名称、收入贡献及其占比
图：2008-2011年迪安诊断前五供应商采购金额及占总采购金额的比重
表：2009-2011年迪安诊断前五供应商名称、采购金额及其占比
图：2008-2011年迪安诊断的研发成本及占营业收入的比重
图：2008-2011年迪安诊断的独立诊断业务收入及毛利率
表：2008-2011年迪安诊断的独立诊断业务（分产品）营业收入及毛利率
表：2010-2011年迪安诊断的独立诊断业务（按客户）营业收入占比
表：2011-2014年迪安诊断（分产品）营业收入预测
表：2008-2012年达安基因营业收入和利润
表：2008-2011年达安基因（分产品）营业收入
图：2008-2011年达安基因（分地区）营业收入构成
图：2008-2011年达安基因（分产品）毛利率
图：2008-2011年达安基因医学检验服务收入及毛利率
表：2011年达安基因从事医学检验业务的子控股公司的净资产、营业收入与净利润
表：2009-2011年永瀚星港营业收入和利润
表：2009-2011年永瀚星港(分产品)营业收入
图：2009-2011年永瀚星港(分产品)营业收入构成
表：2010-2011年永瀚星港（分地区）营业收入
表：2009-2011年永瀚星港(分产品)毛利率
图：2009-2011年永瀚星港前五客户营业收入及占同期营业收入的比重
表：2009-2011年永瀚星港前五客户名称、收入贡献及其占比
图：2009-2011年永瀚星港前五供应商采购金额及占总采购金额的比重
表：2009-2011年永瀚星港前五供应商名称、采购金额及其占比
图：2009-2011年永瀚星港研发投入及占比
表：杭州艾迪康独立医学实验室分布及成立时间

Industry Chain of Independent Clinical Laboratory
Comparison of Independent Clinical Laboratory between China and the USA by Undertaker
Policies Concerning Independent Clinical Laboratory Industry in China, 2010-2011
Market Share of Independent Clinical Laboratory Industry in the U.S. by Diagnostic Item, 2003-2010
Market Share of Medical Diagnostics in the USA by Undertaker, 2010
Revenue and Profit of Quest Diagnostics, 2007-2011
Revenue Structure of Quest Diagnostics by Business, 2011
Major M&As of Quest Diagnostics, 2006-2011
Revenue and Profit of Labcorp, 2007-2011
Revenue Breakdown of Labcorp by Business, 2009-2011
Major M&As of Labcorp, 2007-2011
Top 5 Diagnostic Items of Massachusetts General Hospital and Domestic Third-grade Class-A Hospital
Characteristics and Market Share of Major Independent Clinical Laboratories in China, by the End of 2011
Market Size and Growth Rate of In Vitro Diagnostic Industry in China, 2007-2014E
Market Scale and Growth Rate of In Vitro Diagnostic Reagent in China, 2007-2014E
Structure of In Vitro Diagnostic Reagent in China, 2011
Business Revenue and Diagnostics Revenue of Medical Institutions in China, 2010
Number of Visits in Hospitals and Basic Medical Institutions, 2008-2011
Number of Public and Non-public Hospitals in China, 2008-2011
Layout of D.A. Diagnostics’ Independent Clinical Laboratory
Revenue and Profit of D.A. Diagnostics, 2008-2012
Revenue Breakdown of D.A. Diagnostics by Business, 2008-2011
Revenue Structure of D.A. Diagnostics by Business, 2008-2011
Revenue Breakdown of D.A. Diagnostics by Region, 2008-2011
Revenue Structure of D.A. Diagnostics by Region, 2008-2011
Gross Margin of D.A. Diagnostics by Business, 2008-2011
D.A. Diagnostics’ Revenue from Top 5 Clients and % of Total Revenue, 2008-2011
Name List and Revenue Contribution of D.A. Diagnostics’ Top 5 Clients, 2009-2011
D.A. Diagnostics’ Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2011
Name List and Procurement Contribution of D.A. Diagnostics’ Top 5 Suppliers, 2009-2011
R&D Costs and % of Total Revenue of D.A. Diagnostics, 2008-2011
Revenue and Gross Margin of D.A. Diagnostics’ Independent Diagnostics Business, 2008-2011
Revenue and Gross Margin of D.A. Diagnostics’ Independent Diagnostics Business by Product, 2008-2011
Revenue Structure of D.A. Diagnostics’ Independent Diagnostics Business by Client, 2010-2011
Forecast of D.A. Diagnostics’ Revenue by Business, 2011-2014E
Revenue and Profit of DAAN Gene, 2008-2012
Revenue Breakdown of DAAN Gene by Product, 2008-2011
Revenue Structure of DAAN Gene by Region, 2008-2011
Gross Margin of DAAN Gene by Product, 2008-2011
Revenue and Gross Margin Of DAAN Gene’s Independent Diagnostics Business, 2008-2011
Net Assets, Revenue and Net Income of DAAN Gene’s Subsidiaries Engaging in Independent Diagnostics Business, 2011
Revenue and Profit of NYMPHAVN Biotechnology, 2009-2011
Revenue Breakdown of NYMPHAVN Biotechnology by Product, 2009-2011
Revenue Structure of NYMPHAVN Biotechnology by Product, 2009-2011
Revenue Breakdown of NYMPHAVN Biotechnology by Region, 2010-2011
Gross Margin of NYMPHAVN Biotechnology by Product, 2009-2011
NYMPHAVN Biotechnology’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2011
Name List and Revenue Contribution of NYMPHAVN Biotechnology’s Top 5 Clients, 2009-2011
NYMPHAVN Biotechnology’s Procurement from Top 5 Suppliers and % of Total Procurement, 2009-2011
Name List and Procurement Contribution of NYMPHAVN Biotechnology’s Top 5 Suppliers, 2009-2011
R&D Costs and % of Total Revenue of NYMPHAVN Biotechnology, 2009-2011
Distribution and Established Date of Adicon’s Independent Clinical Laboratory